EI
KRYS icon

Ethic Inc’s Krystal Biotech KRYS Stock Holding History

Ethic Inc’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$448K Buy
1,206
+40
+3% +$12K 0.01% 980
2026
Q1 		$301K Buy
1,166
+203
+21% +$54K ﹤0.01% 1035
2025
Q4 		$237K Buy
+963
New +$203K ﹤0.01% 1085
2025
Q2 		– Sell
-1,431
Closed -$250K – 1265
2025
Q1 		$250K Buy
+1,431
New +$241K 0.01% 1005
2024
Q4 		– Sell
-1,142
Closed -$203K – 1191
2024
Q3 		$203K Sell
1,142
-131
-10% -$25.3K 0.01% 1004
2024
Q2 		$234K Buy
1,273
+131
+11% +$22K 0.01% 980
2024
Q1 		$203K Sell
1,142
-516
-31% -$71.7K 0.01% 1003
2023
Q4 		$206K Sell
1,658
-185
-10% -$20.5K 0.01% 978
2023
Q3 		$214K Sell
1,843
-475
-20% -$58K 0.01% 916
2023
Q2 		$272K Buy
+2,318
New +$237K 0.01% 819
2023
Q1 		– Sell
-2,629
Closed -$208K – 987
2022
Q4 		$208K Buy
+2,629
New +$195K 0.01% 819

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ethic Inc's KRYS Position: Q2 2026 in Review

Ethic Inc increased its Krystal Biotech (KRYS) stake by 3.4% in Q2 2026, buying an estimated $12K and bringing the position to 1,206 shares worth $448K. The position accounts for 0.01% of the portfolio, ranked #980.

Ethic Inc first reported a position in KRYS in Q4 2022 and has held it in 11 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Ethic Inc held 1,206 shares of Krystal Biotech worth $448K as of Q2 2026.
  • Ethic Inc bought 40 Krystal Biotech shares in Q2 2026, an estimated $12K.
  • Krystal Biotech made up 0.01% of Ethic Inc's portfolio in Q2 2026, its #980 holding.
  • Ethic Inc first reported a position in Krystal Biotech in Q4 2022 and has held it in 11 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Ethic Inc's 13F filing for Q2 2026, filed 29 Jul 2026.